oliceridine   Click here for help

GtoPdb Ligand ID: 7334

Synonyms: Olinvyk® | TRV130 | TRV130A
Approved drug PDB Ligand
oliceridine is an approved drug (FDA (2020))
Compound class: Synthetic organic
Comment: Oliceridine (TRV130) is an opioid compound. It was developed to exhibit biased-signalling (specifically bias towards G protein signalling), with the aim of reducing the adverse effects associated with use of other opioid drugs [1-2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 71.62
Molecular weight 386.2
XLogP 3.12
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1ccsc1CNCCC1(CCOC2(C1)CCCC2)c1ccccn1
Isomeric SMILES COc1ccsc1CNCC[C@]1(CCOC2(C1)CCCC2)c1ccccn1
InChI InChI=1S/C22H30N2O2S/c1-25-18-7-15-27-19(18)16-23-13-10-21(20-6-2-5-12-24-20)11-14-26-22(17-21)8-3-4-9-22/h2,5-7,12,15,23H,3-4,8-11,13-14,16-17H2,1H3/t21-/m1/s1
InChI Key DMNOVGJWPASQDL-OAQYLSRUSA-N
No information available.
Summary of Clinical Use Click here for help
Oliceridine (TRV130) is administered intravenously. It was evaluated in human clinical trial for the treatment of acute severe pain [3]. Click here to view the full list of oliceridine trials registered at ClinicalTrials.gov. Oliceridine received FDA approval in August 2020, for the management of acute pain that requires intravenous opioid analgesia and that is not adequately responsive to alternative treatments.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Oliceridine is an agonist of the opioid μ receptor (OPRM1) [1].
Pharmacokinetics Click here for help
Absorption/Distribution
Initial pharmacokinetic and pharmacodynamic data from clinical use of this compound is reported by Soergel et al (2014) [3].